SuperworthPTC Therapeutics PTCT
- Market cap
- $5.1B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 5.0×
- EV/EBIT
- 27.2×
- Revenue, 12 months
- $1B
- −43% on a year ago
- Net margin
- −3.8%
- Free cash flow yield
- −0.8%
PTC Therapeutics trades at 5.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $1B over the last twelve months, down 43% on a year earlier with a −4% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $196.6M−10% | $307.1M+83% | $210.1M−5% | $186.7M−13% | $196.8M+0% | $213.2M−31% | $1.2B+460% | $178.9M−4% | $211M+7% | $164.7M−23% | $272.6M−77% | $360.5M+102% | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $164.2M−1% | $121.4M−36% | $116.1M−41% | $132.2M−29% | $161.4M−2% | $124.8M+3% | $109M−6% | $113M−15% | $100.2M−38% | $133.1M+7% | $100.9M−7% | $99.2M−12% |
| SG&A | $80.9M+1% | $76.3M−18% | $73.3M−16% | $69.5M−21% | $73.5M−9% | $84.7M+11% | $81M+11% | $85.3M+23% | $84M+14% | $96.9M+14% | $86.2M+7% | $80.6M−5% |
| −$118.2M+73% | $5.8M | −$45.5M−61% | −$40.2M−81% | −$54.5M−54% | −$162.4M | $970.2M | −$35M−13% | $3M | −$71.3M−56% | $45M−95% | $149M | |
| Interest expense | $28.2M+35% | $44.3M+81% | $40.8M+49% | $43.5M+48% | $41.6M+48% | $41.1M−7% | $34.1M−17% | $30.4M−30% | $32.6M−22% | $55.2M+34% | $49M+44% | $48.5M+60% |
| Pre-tax income | −$166.6M+31% | −$157.1M−17% | −$84.7M−37% | −$85.7M−64% | −$98M−41% | −$94.7M−40% | $929.8M | −$71.1M−17% | −$23.1M−77% | −$139.1M+47% | −$2.5M | $97.5M |
| −$33.6M+88% | −$1.3M−93% | $6.9M+73% | $13.4M | $8.7M | −$28.8M+2189% | $63.3M+820% | −$6.2M | −$39M | −$4.1M−86% | $347K−100% | $14M | |
| Net income | −$133M+22% | −$155.8M−9% | −$91.6M−34% | −$99.2M−50% | −$106.7M−20% | −$65.9M−58% | $866.6M | −$64.8M−35% | $15.9M | −$135M+105% | −$2.8M | $83.5M |
| −$1.76+15% | −$2.06−12% | −$1.20−36% | −$1.29−52% | −$1.39−21% | −$0.85−59% | $10.04 | −$0.83−36% | $0.20 | −$1.64+93% | −$0.03 | $0.92 | |
| 75.4M+5% | 75.5M+4% | 76.5M+4% | 76.7M+3% | 76.9M+2% | 77.2M+2% | 86.4M+13% | 78.2M+2% | 87.1M+13% | 82.2M+6% | 82.5M−5% | 92M+18% |
Revenue: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Gross profit: 16 periods, Q1 FY16 to Q4 FY19: not printed by the filing, worked out from its own lines.
R&D: Q1 FY12: 6 months less the 3 months printed beside them.
SG&A: Q1 FY12: 6 months less the 3 months printed beside them.
Operating income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Net income: Q1 FY12: 6 months less the 3 months printed beside them.
EPS, diluted: 10 periods, Q2 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY12 and Q4 FY17: share-days: the 12-month average less the 9-month, weighted by days. 12 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest PTC Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PTCTPTC Therapeutics | $5.1B | n/m | 8.5× | 5.0× | −43% | −3.8% | |
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.3× | 37.7× | 20.8× | +55% | 67.9% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.6× | 51.5× | 2.1× | +9% | 5.0% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| LQDALiquidia | $3.8B | 30.7× | 53.6× | 8.5× | n/m | 30.7% | |
| OGNOrganon | $3.6B | 17.9× | 5.9× | 0.6× | −2% | 3.4% | |
| ALKSAlkermes plc. | $7.3B | 115× | 16.0× | 4.4× | +11% | 4.0% | |
| TGTXTG Therapeutics | $8.3B | 19.8× | 19.4× | 10.4× | +76% | 55.2% | |
| PTGXProtagonist Therapeutics | $9B | 134× | 58.3× | 31.8× | +35% | 29.4% | |
| Peer median | $6B | 36.9× | 44.6× | 7.8× | +35% | 18.1% |
Investors who own it
Investors we follow who held PTC Therapeutics at the end of Jun 30, 2026, from their 13F filings.
- Polen CapitalPolen Capital0.0% of portfolionew
More on PTC Therapeutics
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .